TipRanks on MSN

XORTX highlights new gout genetics research, reshapes board and clarifies financing as Vectus deal nears closing

The latest announcement is out from XORTX Therapeutics Inc ( ($TSE:XRTX) ). On December 31, 2025, XORTX Therapeutics highlighted newly published, ...
TipRanks on MSN

XORTX leans into genetic breakthroughs in gout as it reshapes board and advances oxypurinol

XORTX Therapeutics Inc ( ($TSE:XRTX) ) has shared an announcement. XORTX Therapeutics highlighted newly published, large-scale genetic research ...

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

Clinical Data doubles known genetic factors associated with urate and GoutCALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- ...
BioWorld

Chinese scientists divulge new XOR inhibitors

Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized xanthine ...
Pharmabiz

Xortx Therapeutics announces pioneering research on genome-wide pathogenic pathways in gout

Xortx Therapeutics announces pioneering research on genome-wide pathogenic pathways in gout: Calgary, Alberta Saturday, January 3, 2026, 13:00 Hrs [IST] Xortx Therapeutics Inc., a ...

XORTX Therapeutics Inc.: XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused ...